19.78
1.08 (5.78%)
| Previous Close | 18.70 |
| Open | 19.14 |
| Volume | 880,015 |
| Avg. Volume (3M) | 1,122,896 |
| Market Cap | 1,582,709,888 |
| Price / Sales | 12.25 |
| Price / Book | 6.26 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 3.86% |
| Operating Margin (TTM) | 51.85% |
| Diluted EPS (TTM) | 0.120 |
| Quarterly Revenue Growth (YOY) | 7,882.00% |
| Total Debt/Equity (MRQ) | 15.21% |
| Current Ratio (MRQ) | 5.61 |
| Operating Cash Flow (TTM) | 34.67 M |
| Levered Free Cash Flow (TTM) | 40.54 M |
| Return on Assets (TTM) | -0.40% |
| Return on Equity (TTM) | 2.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Monte Rosa Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -4.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.30 |
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.73% |
| % Held by Institutions | 101.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aisling Capital Management Lp | 31 Dec 2025 | 1,472,331 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BOWEN MATTHEW | 16.93 | - | 4,300 | 72,799 |
| NICKSON PHILIP | - | 18.05 | -5,845 | -105,502 |
| WARMUTH MARKUS | - | 17.50 | -8,000 | -140,000 |
| Aggregate Net Quantity | -9,545 | |||
| Aggregate Net Value ($) | -172,703 | |||
| Aggregate Avg. Buy ($) | 16.93 | |||
| Aggregate Avg. Sell ($) | 17.78 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WARMUTH MARKUS | Officer | 14 Apr 2026 | Sell (-) | 8,000 | 17.50 | 140,000 |
| NICKSON PHILIP | Officer | 09 Apr 2026 | Sell (-) | 5,845 | 18.05 | 105,502 |
| BOWEN MATTHEW | Officer | 06 Apr 2026 | Acquired (+) | 4,300 | 16.93 | 72,799 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |